补充批准 · 说明书变更
批准信:Prior Approval;更新第 12.3 节药代动力学消除半衰期(9.2→13.9 小时),并在第 8.1 节妊娠、第 17 节患者咨询及用药指南中新增妊娠暴露登记信息。
展开审批详情
批准信原文要点
This Prior Approval sNDA provides for revisions in the Prescribing Information (PI) Section 12.3 Pharmacokinetics to update the elimination mean half-life from 9.2 hours to 13.9 hours and to also add text to PI Section 8.1 Pregnancy and Section 17 Patient Counseling Information, and to the Medication Guide, to include information on Pregnancy Exposure Registry.
Labeling-Medication Guide;Labeling-Package Insert(MED GUIDE;PI)
申报事项:说明书/标签变更(Prior Approval)
变更信息:更新第 12.3 节药代动力学消除半衰期(9.2→13.9 小时),并在第 8.1 节妊娠、第 17 节患者咨询及用药指南中新增妊娠暴露登记信息。
来源:Label · 打开摘录来源 ↗